SCHEMBL2028609

SCHEMBL2028609

CCc1n[nH]cc1C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphoric Acid SCHEMBL2026236 0.88 PGK1 (0.31)
SCHEMBL6620138 0.78
SCHEMBL19687235 0.78
SCHEMBL25707783 0.78
SCHEMBL17785870 0.78
SCHEMBL10438305 0.78 HRH3 (0.38)
Hydrochloric Acid SCHEMBL26134141 0.76 TDP1 (0.31)
SCHEMBL15186249 0.76
SCHEMBL34847 0.75
SCHEMBL10369750 0.75 KDM4E (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107759588-A A kind of phenyl (base of pyrazolo [1,5 a] pyridine 3) ketone derivatives 江苏新元素医药科技有限公司 2018-03-06 CN claimed
EP-3867248-B1 PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS NXERA PHARMA UK LTD (GB) 2025-12-10 EP disclosed
US-20250115587-A1 PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS NXERA PHARMA UK LIMITED (GB) 2025-04-10 US disclosed
US-12234227-B2 Pyrazole derivatives as H4 antagonist compounds NXERA PHARMA UK LIMITED (GB) 2025-02-25 US disclosed
WO-2024076670-A2 TETHERED HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF AMGEN INC. (US) 2024-04-11 WO disclosed
WO-2023196283-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2023-10-12 WO disclosed
WO-2023192901-A1 QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS ESCIENT PHARMACEUTICALS, INC. (US) 2023-10-05 WO disclosed
US-11691963-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors AJAX THERAPEUTICS, INC. (US) 2023-07-04 US disclosed
US-20230192667-A1 BETA-LACTAM DERIVATIVES FOR THE TREATMENT OF DISEASES INSILICO MEDICINE IP LIMITED (HK) 2023-06-22 US disclosed
US-20220411403-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. 2022-12-29 US disclosed
WO-2007099323-A2 QUINOLINE DERIVATIVES ASTRAZENECA AB (SE) 2007-09-07 WO disclosed
CN-1154637-C Method for producing substituted pyrazoles �����ɷ� 2004-06-23 CN disclosed
EP-1021416-B1 METHOD FOR PRODUCING SUBSTITUTED PYRAZOLES BASF AG (DE) 2004-05-19 EP disclosed
EP-1320527-A1 METHOD FOR PRODUCING 1 SUBSTITUTED 5-CHLORO-4 METHYL PYRAZOLES BASF AKTIENGESELLSCHAFT (DE) 2003-06-25 EP disclosed
WO-2002026715-A1 METHOD FOR PRODUCING 1 SUBSTITUTED 5-CHLORO-4 METHYL PYRAZOLES BASF AKTIENGESELLSCHAFT (DE) 2002-04-04 WO disclosed
US-6229022-B1 REACTING CARBONYL COMPOUNDS WITH HYDRAZINE, ITS HYDRATE OR SALTS IN THE PRESENCE OF SULFURIC ACID AND IODINE OR AN IODINE LIBERATING COMPOUND BASF AKTIENGESELLSCHAFT (DE) 2001-05-08 US disclosed
EP-1021416-A1 METHOD FOR PRODUCING SUBSTITUTED PYRAZOLES BASF AKTIENGESELLSCHAFT (DE) 2000-07-26 EP disclosed
CN-1261351-A Process for preparing substituted pyrazoles BASF AG (DE) 2000-07-26 CN disclosed
WO-1998058914-A1 METHOD FOR PRODUCING SUBSTITUTED PYRAZOLES BASF AKTIENGESELLSCHAFT (DE) 1998-12-30 WO disclosed
EP-0366329-A1 Halogeno-4-methylpyrazoles and process for preparing the same NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) 1990-05-02 EP disclosed